Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bendamustine Plus Bortezomib Plus Dexamethasone in the Treatment of Stage II/III Relapsed or Refractory Multiple Myeloma

NCT01168804 is registered in ClinicalTrials.gov with Austrian Forum Against Cancer as lead sponsor.

NCT NCT01168804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01168804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bendamustine Plus Bortezomib Plus Dexamethasone in the Treatment of Stage II/III Relapsed or Refractory Multiple Myeloma
Lead sponsor
Austrian Forum Against Cancer
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2010
Completion date
May 31, 2013
Enrollment
79 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma